Who signed the Lipocine (LPCN) 8-K related to the H.C. Wainwright conference?

The report was signed on behalf of Lipocine Inc. by Mahesh V. Patel, the company’s President and Chief Executive Officer, dated September 16, 2026.

Lipocine posts H.C. Wainwright investor presentation

Q: What did Lipocine Inc. (LPCN) announce in this 8-K filing?

Lipocine Inc. announced that it presented on September 16, 2026 at the H.C. Wainwright 28th Annual Global Investor Conference and that its investor presentation is furnished as Exhibit 99.1, making the materials publicly accessible.

Q: When and where did LPCN present at the H.C. Wainwright conference?

Lipocine presented on September 16, 2026 at the H.C. Wainwright 28th Annual Global Investor Conference, which was held September 14–16, 2026 in New York City, NY.

Q: Which exhibits did Lipocine (LPCN) include with this 8-K?

The filing includes Exhibit 99.1, titled “H.C. Wainwright 28th Annual Global Investment Conference Presentation,” and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Lipocine Inc. (LPCN) filed a report stating that on September 16, 2026 it presented at the H.C.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. (LPCN) filed a report stating that on September 16, 2026 it presented at the H.C. Wainwright 28th Annual Global Investor Conference in New York City, held September 14–16, 2026. The company furnished its conference presentation as Exhibit 99.1 and incorporated it by reference into this report.

The filing also lists a Cover Page Interactive Data File as Exhibit 104. No financial results, guidance, or transactional events are described; the disclosure centers on making Lipocine’s investor presentation publicly available to the market.

Insights

Analyzing...

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Presentation date: September 16, 2026 Conference dates: September 14–16, 2026 Exhibit 99.1: 1 presentation +1 more

4 metrics

Presentation date September 16, 2026 Date Lipocine presented at the H.C. Wainwright 28th Annual Global Investor Conference

Conference dates September 14–16, 2026 Overall dates of the H.C. Wainwright 28th Annual Global Investor Conference

Exhibit 99.1 1 presentation H.C. Wainwright 28th Annual Global Investment Conference presentation furnished as an exhibit

Exhibit 104 1 data file Cover Page Interactive Data File embedded within the Inline XBRL document

Key Terms

Emerging growth company, Section 12(b) of the Act, Inline XBRL

3 terms

Emerging growth company regulatory

"405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 12(b) of the Act regulatory

"Securities registered pursuant to Section 12(b) of the Act"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) announce in this 8-K filing?

Lipocine Inc. announced that it presented on September 16, 2026 at the H.C. Wainwright 28th Annual Global Investor Conference and that its investor presentation is furnished as Exhibit 99.1, making the materials publicly accessible.

When and where did LPCN present at the H.C. Wainwright conference?

Lipocine presented on September 16, 2026 at the H.C. Wainwright 28th Annual Global Investor Conference, which was held September 14–16, 2026 in New York City, NY.

Which exhibits did Lipocine (LPCN) include with this 8-K?

The filing includes Exhibit 99.1, titled “H.C. Wainwright 28th Annual Global Investment Conference Presentation,” and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Does this Lipocine (LPCN) 8-K provide any earnings or financial results?

No. The report focuses on Lipocine’s participation in the H.C. Wainwright investor conference and the furnishing of its presentation as Exhibit 99.1. It does not describe earnings, financial results, or new financing transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/16/2026 - 04:38 PM Accepted by SEC EDGAR 09/16/2026 - 04:38 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 16, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On September 16, 2026, the Company presented at H.C. Wainwright 28^th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description

99.1		H.C. Wainwright 28^th Annual Global Investment Conference Presentatin

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.